Indications
Stable regular wide complex tachycardia. Stable irregular wide complex tachycardia. VF or pulseless VT.
Contraindications
Hypersensitivity, severe sinus node dysfunction, second- or third-degree heart block or bradycardia causing syncope (unless a working pacemaker is in place), cardiogenic shock.
Adult dose
Stable regular wide complex tachycardia: 150 mg IV over 10 minutes. May repeat once as needed.
Stable irregular wide complex tachycardia: 150 mg IV over 10 minutes. May repeat once as needed. In WPW, give it after procainamide.
VF or pulseless VT not responding to CPR, defibrillation and a vasopressor: 5 mg/kg IV, max 300 mg. 2025 AHA ACLS: 300 mg IV/IO bolus first, then a second dose of 150 mg IV/IO.
Infusion for recurring VF or unstable VT (FDA label): 150 mg over the first 10 minutes (15 mg/min), then 360 mg over the next 6 hours (1 mg/min), then 540 mg over the remaining 18 hours (0.5 mg/min). After 24 hours, keep going at 0.5 mg/min (720 mg per 24 hours). For breakthrough VF or unstable VT, repeat 150 mg over 10 minutes.
Pediatric dose
Stable regular wide complex tachycardia, when it is not treated as SVT with aberrancy: 5 mg/kg IV (max 150 mg) over 10 minutes.
Cardiac arrest, VF or pulseless VT: 5 mg/kg IV, max 300 mg.
Infusion (FDA label): no pediatric dose. Safety and effectiveness in children have not been established.
Route
IV, IO
Special considerations
Use only one antidysrhythmic at a time. Don't stack a second one on top.
In WPW, procainamide comes before amiodarone.
When your patient can't tolerate diltiazem or metoprolol, as in CHF, it can be used for rate control. Use caution if they aren't anticoagulated, because it can convert the rhythm.
Avoid it during breastfeeding.
Follow your local protocols. Sources: National Model EMS Clinical Guidelines (NASEMSO, 2022): Tachycardia with a Pulse; Cardiac Arrest (VF/VT/Asystole/PEA); Purpose and Notes. AHA ACLS algorithms (2025): Adult Cardiac Arrest Algorithm. FDA drug labels: Nexterone. Levels from the National EMS Scope of Practice Model (2019).